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Purpose: Recommendations from American Society of Clinical Oncology (ASCO) emphasize 
the critical need to understand current trends in fertility preservation (FP) among the two sets 
of primary healthcare providers involved in oncofertility: the oncologists and the 
gynecologists. This study is aimed at understanding the healthcare providers’ knowledge, 
attitudes and barriers in oncofertility across India.  
Methods: An eighteen-item oncofertility survey was designed and directed to 77 oncologists 
and 214 gynecologists across India. The responses were analysed using descriptive statistical 
methods and the oncofertility trends between the two groups was studied.  
Results: The total response rate was 34% with 49 of 214 oncologists (23%) and 49 of 77 
gynecologists (64%), participating in the survey. The awareness of ASCO fertility preservation 
guidelines among oncologists and gynecologists was 53% and 59.5%, respectively. About 48% 
of oncologists felt knowledgeable about sperm banking while 52% knew about oocyte freezing 
but not about other options. On the other hand, among gynecologists, 38% reported inadequate 
knowledge of testicular or ovarian tissue cryopreservation. About 85% of oncologists reported 
routine referral of cancer diagnosed patients for FP, while 75% of gynecologists reported 
routine FP discussion with patients. Healthcare providers from both groups perceived the major 
barriers in oncofertility to be, ‘financial burden on the patient’ (73-86%) and, ‘lack of patient 
awareness’ (71-79.5%). 
Conclusion: Effective collaboration between oncologists and gynecologists is essential to 
establish a successful fertility preservation program. Economic burden on the patient and lack 
of patient and physician awareness are limiting factors which need to be overcome. 
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 Introduction:  
The estimated cancer incidence in India is 1.15 million new diagnoses as of 2018, with 
diagnoses expected to almost double by 2040.1 With advancements in cancer treatment, early 
diagnostics, and increased investment in healthcare technology, there has been an increase in 
cancer survival rates, especially in developed countries.2 However, survival rate does not 
equate to improved quality of life. A follow-up study on a cohort of childhood cancer survivors 
in India reported impaired reproductive capacity as a common long-term effect in 
approximately 25% of patients.3 This brings about an urgent need for awareness and effective 
implementation of oncofertility services before the commencement of cancer treatment.  
 
Oncofertility is a rapidly emerging field that aims to increase awareness of fertility preservation 
(FP) among cancer patients and healthcare providers on a global scale.4 Along with a well-
orchestrated involvement of various medical experts to address the needs of fertility problems 
in cancer patients, oncofertility demands a merger of two medical specialities: oncology and 
reproductive medicine.4 Despite the American Society of Clinical Oncology (ASCO) 
recommending guidelines to offer fertility preservation services to oncological patients,5 85% 
of childhood cancer survivors in India reported that no information was provided to them about 
the possible risk of infertility due to treatment.6 This lack of information dissemination 
resonates the need to understand the attitudes, knowledge and barriers in oncofertility among 
healthcare providers, given the important role they play in FP decision making.7 To the best of 
our knowledge, there have been no studies in India addressing the oncofertility trends among 
oncologists nor an assessment of these trends between oncologists and gynecologists, to reflect 
the exchange of communication and practice behaviors between the two specialities. Hence, 
the present study is aimed at assessing the knowledge levels, perceptions, and current 
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challenges in oncofertility among the two most important groups of healthcare providers 
involved in an oncofertility program: oncologists and gynecologists.  
 
Methods:  
An 18-item survey was designed constituting four domains – knowledge about fertility 
preservation (FP) techniques, attitudes, existing barriers in oncofertility, and demographics 
(Supplementary Table 1). The survey design was based on review of literature from developed 
countries,8-11 and in collaboration with the Oncofertility Consortium. Content validity for the 
survey was performed by five experts in the fields of medical oncology and gynecology. A 
pilot survey was administered to a small group of healthcare providers to confirm the 
comprehensibility of the questions, the unpublished results of which are not included in the 
present study. The survey was then randomly distributed to oncologists and gynecologists 
attending various national conferences or academic meetings across the country (specific to the 
field of oncology and gynaecology) or even visits to the practitioners’ clinics between May to 
November 2019. The first page of the survey contained aims of the survey along with a consent 
form; healthcare providers willing to participate were requested to sign the informed consent 
before beginning the survey.  
The survey contained a total of 18 questions of which 10 were aimed at understanding the 
knowledge, attitudes, practice trends in oncofertility, existing barriers, and suggestions for 
effective use of FP; the remaining 8 questions covered the demographics of the survey 
responder and contextual details such as the number of new cancer patients treated in a month 
and the patient age groups. Two questions were dichotomous, 8 were multiple choice where 
only 1 response could be selected; 1 question was multiple response where more than one 
answer could be selected and 1 was an open-ended question with space provided for 
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respondents to give their suggestions. 6 questions were assessment tools with 3- or 4-point 
grading scales to ascertain the levels of knowledge or attitude. The multiple response question 
had a list of nine common oncofertility barriers from which a participant could select more than 
one option.  
The survey responses were analysed using IBM SPSS Statistics Software after assigning 
numerical values to the responses (Yes=1, No=0). The data was analysed using descriptive 
statistics and percentages were calculated based on number of responses for each of the 
questions. For analysis of certain questions that contained grading scales or multiple choice 
(Q2, Q4, Q5, Q7), the response options such as ‘not aware’, ‘aware but not adequate 
knowledge’, ‘knowledgeable’ and ‘very knowledgeable’ were combined into two categories 
such as, ‘inadequate knowledge’ and ‘knowledgeable’. Questions with high variation in  
responses, such as more than half of the respondents not answering, were not analysed in the 
present study. The study was approved by the Institutional Ethics committee of Kasturba 
Medical College & Kasturba Hospital, Manipal (No: IEC 880/2017).  
 
Results:  
The total response rate to the survey was 34% with 49 out of 77 responses (64%) received from 
gynecologists and 49 out of 214 responses from oncologists (23%), across various 
subspecialties such as pediatric hematology and oncology, medical oncology, radiation and 
surgical oncology. The demographics of the healthcare providers participating in the survey 
are listed in Table 1 describing characteristics such as age, gender, work setting, and experience 
in their field. 
Awareness and attitudes towards fertility preservation: In the present study, 53% of 
oncologists (26 of 49) and 59.5% of gynecologists (28 of 47) reported awareness of the current 
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ASCO guidelines regarding fertility preservation. However, a considerable number in both the 
groups (40-47%) seemed to be unaware (Fig 1A).  In order to assess attitudes towards fertility 
preservation, the survey participants were asked to give their opinion on the statement, 
‘offering fertility preservation compromises cancer treatment’. About 71% of oncologists (34 
of 48) and 75% of gynecologists (36 of 49) disagreed with the statement, while 22-25% in both 
groups felt that cancer treatment is compromised. 2-4% of the participants from both groups 
chose not to respond to the statement.  
Knowledge of fertility preservation options: When asked about their knowledge of different 
fertility preservation options currently available for both prepubertal and adult cancer patients, 
52% of oncologists (25 of 48) reported adequate knowledge of sperm banking and 48% (23 of 
48) had knowledge of oocyte freezing, but >60% of the participants in this group did not have 
adequate knowledge of other fertility preservation options.  On the other hand, the reproductive 
specialists were knowledgeable of the most widely available options for adult cancer patients 
such as sperm banking (41 of 49 - 83.6%), oocyte freezing (44 of 49 - 89.7%), in vitro 
fertilization followed by embryo freezing (IVF) (44 of 49 - 89.7%) and Gonadotropin releasing 
hormone agonist (GnRHa) pre-treatment (39 of 48 - 81.2%). Interestingly, about 39-41% of 
gynecologists reported inadequate knowledge of prepubertal/pubertal FP options such as 
immature testicular tissue and ovarian tissue cryopreservation (Fig 1B).  
Patient referral for fertility preservation: To determine the practice trends in oncofertility 
among oncologists and gynecologists, participants were asked about the frequency of initiating 
a fertility preservation discussion with their cancer-diagnosed patients. Among oncologists, 
81.6% (40 of 49) stated that they routinely, if not mostly, initiated FP discussions, and 85% 
(39 of 46) of them even reported referring their patients for FP services immediately after 
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diagnosis. A similar trend was seen among gynecologists, with 75% (36 of 48) of them 
reporting routine fertility preservation discussions with cancer patients (Fig 1C).  
Comfort level to discuss fertility preservation with patients: When asked to rate the comfort 
level in discussing the various FP  options with cancer patients, about 87%  oncologists (42 of 
48) reported being comfortable in discussing sperm banking, and 79% (38 of 48) with oocyte 
banking. There appeared to be a decline in their comfort level, however, when discussing the 
other options such as testicular tissue cryopreservation (30 of 45 - 67%), ovarian tissue freezing 
(32 of 46 - 69.5%), IVF (30 of 46 - 65%) or GnRHa pre-treatment (30 of 45 - 67%). About 90-
94% gynecologists felt comfortable discussing most options, but even among this group a small 
proportion were not at ease when discussing testicular (15%), ovarian (11.5%) tissue freezing 
or GnRHa pre-treatment (12%) options (Fig 1D).  
Barriers and suggestions for effective oncofertility implementation in India:  In the present 
study, nine common barriers were listed in the questionnaire with the responder allowed to 
select more than one option. The study revealed an overall consensus among participants in 
perception of oncofertility barriers, with 73-82% of healthcare providers from both groups 
perceiving ‘financial burden on patient’ as an important barrier to fertility preservation, 
followed by ‘lack of patient awareness’ (71-80%). Other major barriers perceived by 
oncologists and reproductive specialists alike were ‘lack of physician awareness’ (55-57%) and 
‘time to treatment’ (40-43%), referring to the time from diagnosing a cancer to commencement 
of treatment (Fig 2). However,  opinions seemed to differ between the two groups for certain 
barriers, such as, ‘lack of FP facilities’ (oncologists – 61%; Gynecologists - 26.5%), ‘ cultural 
and religious barriers’(oncologists – 35%; gynecologists - 16%), and ‘age of patient’ 
(oncologists – 43%; gynecologists - 16%). 
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Among the survey participants (56%), 25 of 49 oncologists (51%) and 31 of 49 gynecologists 
(63%) suggested that there was a need to strengthen utilization of FP in India. The primary 
suggestion given by 61-64% of the healthcare providers in both the groups was ‘awareness and 
sensitization of healthcare providers in fertility preservation’, and 52% of oncologists felt there 
was a need for availability of more FP units closer to cancer hospitals for immediate 
intervention and minimum discomfort to the patients. ‘Creating a social awareness to educate 
the general public’, was suggested by 29% of gynecologists for effective implementation of 
oncofertility programs. Other suggestions included, ‘affordable costs’ (8-13%), ‘need for 
fertility preservation counselling’ (8-13%) and a need for consensus guidelines (13-16%), 
among participants from both groups.  
  
Discussion: 
The present study investigated oncofertility attitudes, knowledge, and practice trends amongst 
Indian oncologists and gynecologists, along with their perception of oncofertility barriers. 
Despite reduced awareness of the international guidelines and inadequate knowledge of some 
of the available services, majority of the oncologists were found to routinely refer their 
oncological patients for FP services, soon after cancer diagnosis. Similarly, gynecologists 
reported routine FP discussions with patients before the commencement of cancer therapy. 
While this is a promising finding, it highlights the need for oncofertility awareness programs 
among oncologists and reproductive specialists to enable effective oncofertility counselling 
and referral. The common oncofertility barriers perceived by both the groups were, economic 
burden to the patient and lack of patient and physician awareness on fertility preservation. To 
the best of our knowledge, this is the first study in India to assess oncofertility knowledge and 
attitudes among oncologists and relate their practice trends with that of gynecologists. 
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In the present study, only 50-53% of the healthcare providers from both medical specialities 
were aware of the ASCO fertility preservation guidelines5 that recommend routine discussion 
of FP options with cancer diagnosed patients. This finding is in line with a Dutch study on 23 
medical professionals that included oncologists and gynecologists, citing lack of awareness of 
FP guidelines among healthcare providers as one of the significant barriers, despite availability 
of this information in journals and websites.12 Also, the perspectives of healthcare providers 
towards oncofertility played a key role in FP discussions. In the present study, majority of the 
oncologists (70.8%) and gynecologists (75%) did not perceive that fertility preservation 
compromises cancer treatment. This finding is in contrast to a Canadian interview-based 
qualitative study on 22 clinicians, including oncologists and fertility specialists, which reported 
that clinicians perceived patient survival as the primary factor and infertility as non-fatal, 
therefore, fertility preservation is secondary and could interfere or even delay cancer 
treatment.13  
Despite the reduced awareness of guidelines, it was interesting to see that a majority of 
oncologists and reproductive specialists participating in the present study reported routine 
fertility preservation discussions and referrals to FP services, before commencement of cancer 
therapy.  However, this is in stark contrast with the reality of oncofertility consultations in 
India, where only 15% of 21 childhood cancer survivors reported to have received counselling 
on infertility risks despite treatment plans involving alkylating chemotherapy, radiotherapy or 
gonadal surgery.6 The need for FP counselling after a cancer diagnosis is emphasized further 
with the findings of a study on newly cancer diagnosed patients in India, which reported that 
87% of cancer patients wish to know the future risks associated with their disease and 
treatment, to allow for positive decision-making.14 Individuals who have been counselled for 
FP have been shown to cope better and have lower distress pertaining to fertility, along with 
an improved quality of life.15 Inadequate or lack of information from the healthcare providers 
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could add to the complexities of decision making during emotionally vulnerable times such as 
soon after a cancer diagnosis.  
The role of oncologists and gynecologists is pivotal in a successful oncofertility program, as 
the former is the first point of contact for cancer diagnosed patients and the latter plays a key 
role in fertility preservation discussion with the patients.4 Their knowledge of FP options and 
comfort in discussing adult and prepubertal options would likely correlate directly with the 
frequency of these discussions with their patients.16 In the present study, knowledge gaps were 
seen among oncologists and even the reproductive specialists, particularly with prepubertal 
options such as testicular and ovarian tissue cryopreservation. This finding correlated with their 
admittance of reduced comfort level in discussing these options with their oncological patients. 
Further, the lack of comfort among oncologists to discuss IVF or GnRHa pre-treatment could 
reflect the dearth of knowledge in this area. In concurrence with our finding, a study from the 
UK reported that oncologists felt knowledgeable mainly about sperm cryopreservation and 
knew little about other options, but referred patients for FP nevertheless, as they perceived it 
as a priority.8  While in-depth knowledge on gonadal toxicity and infertility may not be required 
for counselling, identifying the need for fertility preservation and awareness of the nearest FP 
unit is essential.8 Disparity of knowledge and lack of ease in discussing FP, even among 
reproductive specialists for prepubertal options, highlights the need for further education and 
awareness in this field. Providing healthcare providers with educational resources such as 
toolkits, brochures or through Continuing Medical Education (CME) programs would improve 
the frequency and quality of fertility preservation discussions with their patients.9,12,17 
Barriers in oncofertility hinder the effective execution of fertility preservation services leading 
to their under-implementation. In India, insurance coverage is not provided for FP 
procedures,10 making financial burden to the patient one of the biggest challenges to overcome 
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in the country. Economic burden to the patient is one of the significant barriers perceived by 
both groups of healthcare providers participating in the present study, followed by lack of 
patient and physician awareness. These findings can be corroborated by another study 
conducted in India among gynecologists who also reported social and medical barriers such as 
lack of patient interest, physician awareness and unavailability of fertility preservation 
services.18 Lack of insurance coverage or funding and high costs to patients appear  to 
be common economic barriers in developing countries19,20 that need to be addressed. Similar 
barriers have been reported in developed countries as well, along with other religious or cultural 
restrictions and legal barriers.10,21  
Other important barriers cited by healthcare providers participating in the present study include 
the physician’s lack of awareness, and ‘time to treatment’. Although FP plays a crucial role in 
the quality of life post-treatment, the options may not always be offered, especially to 
prepubertal children and women, due to the urgency to initiate cancer treatment.22,23 Kohler et 
al, reported gender disparity in oncofertility referrals, with around 50% healthcare providers 
referring male pubertal patients for FP but only 13% referrals for female pubertal patients 
which could be attributed to lack of knowledge among physicians, as well as inadequate time 
prior to treatment for services such as IVF or oocyte banking.24 A similar finding was reported 
by Peddie et al,  where one of the reasons why fertility preservation was not discussed with 
cancer diagnosed patients was the belief that treatment had to start urgently and that the delay 
due to FP could not be justified, however, not all the medical professionals were certain of the 
time taken for each of the FP procedures. 25  
In addition to the barriers cited in the present study, healthcare providers also gave their 
suggestions, some of which are potential solutions for a successful establishment of 
oncofertility in the country Suggestions included increasing awareness and sensitization of 
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healthcare providers about FP, an availability of more FP units, a need for consensus 
guidelines, and affordable costs. These suggestions are in line with earlier studies, which also 
included developing reliable referral pathways and training of patient navigators and oncology 
nurses about fertility issues and available options.7,12,16 
In conclusion, this study shows that the two primary healthcare providers involved in an 
onofertility program, i.e, oncologists and gynecologists, agree upon the importance of 
preserving fertility before cancer therapy. It also reveals the necessity of more information on 
FP options. The study highlights the major barriers perceived between the two specialties in 
India, which brings about a need to develop strategies for increased medical and social 
awareness for effective implementation of FP services. One of the strategies for an effective 
nationwide implementation of oncofertility programs could include the formation of a network 
similar to the National Physicians Cooperative (NPC), a network that includes 83 institutions 
within the USA committed to  FP for oncological and non-oncological medical 
conditions that could impact fertility.26 Also, the creation of fertility preservation consortiums 
along the lines of the Oncofertility Consortium, that also includes NPC, would facilitate global 
networking, knowledge sharing, and resource distribution in fertility preservation among 
medical professionals, thereby helping establish a standard-of-care in oncofertility practice27 
in India.  
The present study has its limitations, one of which is the random recruitment of participants 
attending oncology and gynecology national conferences or meetings, rendering it likely to 
have a selection bias. Another limitation is the inclusion of all gynecologists, not all of them 
being experts in fertility management or andrology, whose awareness of the various FP options 
may be limited. Details pertaining to the types of cancers treated by oncologists, the frequency 
of treating adolescent and young adult patients requiring oncofertility services, and whether 
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gynecologists also treated cancer patients are areas that need to be focused upon in future 
studies. 
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Figure 1: Trends in fertility preservation among oncologists and gynecologists in India. 
(A) Awareness of ASCO- fertility preservation guidelines among healthcare providers.  (B) 
Healthcare provider’s knowledge of various fertility preservation options. The various fertility 
preservation options in X axis are Sperm freezing (SF), Testicular tissue cryopreservation 
(TTC), Oocyte banking (OB), Ovarian tissue cryopreservation (OTC), IVF followed by 
embryo freezing (IVF) and GnRHa pre-treatment (GnRHa). (C) Frequency of initiating fertility 
preservation discussions with cancer patients. (D) Proportion of healthcare providers 
comfortable in discussing the various fertility preservation options with cancer patients.  
  





Table 1: Demographics of healthcare providers participating in the survey.  
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Supplementary Table 1: The 18-item questionnaire administered to oncologists and 
gynaecologists to assess the healthcare provider knowledge, attitudes and barriers in fertility 
preservation. 
Q1. Are you familiar with the American Society of Clinical Oncology (ASCO) guidelines 




Q2. How would you grade your knowledge of fertility preservation options available for 
patients affected with cancer?  Please tick the appropriate box. 








a. Semen cryopreservation 
    
b. Testicular tissue 
              cryopreservation     
c. Oocyte cryopreservation 
    
d.  Ovarian tissue 
cryopreservation     
e. In vitro fertilization with 
embryo cryopreservation     
f. Pre-treatment with GnRH 
agonists     
 




c. Do not know 
 
Q4. How often do you initiate a discussion on effects of cancer treatment on fertility? 
a. Never 
b. Only when asked 
c. Occasionally 
d. Most of the time 
e. Routinely 
 
Q5. When do you refer your patients for fertility preservation consultation? 
a. Immediately after diagnosis 
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b. Before planning treatment 
c. During cancer treatment 






Q6. How long do you feel is the time required for a cancer patient to complete the fertility 
preservation procedure? Please tick the appropriate box. 
Fertility preservation options <1 week 2-3weeks 1 month 
Do not 
know 
a. Semen cryopreservation 
    
b. Testicular tissue cryopreservation 
    
c. Oocyte cryopreservation 
    
d. Ovarian tissue cryopreservation     
    
e. In vitro fertilization with embryo 
cryopreservation     
f. Pre-treatment with GnRH agonists 
    
 
Q7. How comfortable are you to discuss the fertility preservation options with your 
patients? Please tick the appropriate box. 
Fertility preservation options 
Not comfortable 
at all 
Comfortable  Very 
comfortable 
a. Semen cryopreservation 
   
b. Testicular tissue cryopreservation 
    
c. Oocyte cryopreservation 
   
d. Ovarian tissue cryopreservation                              
    
e. In vitro fertilization with embryo 
cryopreservation    
f. Pre-treatment with GnRH agonists 




Q8. What is the proximity to the nearest fertility preservation unit you can refer your 
patients to? 
a. Same hospital 
b. Same city 
c. <100kms 
d. >100 kms 
e. Don’t know 
 
Q9. Which factors may be considered as barriers for providing fertility preservation to 
cancer patients? (More than one option may be selected.) 
a. Time to treatment 
b. Financial burden on patient 
c. Lack of patient awareness on importance of fertility preservation 
d. Lack of awareness among healthcare providers about availability of fertility 
preservation options  
e. Lack of fertility preservation facilities nearby 
f. Lack of referrals  
g. Cultural/religious restrictions 
h. Age of patient 
i. Emotional status of patient 
j. Others ……………………………………………………………………….. 
 
 
Q10. Please give your recommendations for effective utilization of fertility preservation 












Details of survey participant 
 







Q12. Gender of participant  
a. Male 
b. Female  
 
Q13. Area of specialization 
a. General Medicine 
b. Medical Oncology 
c. Paediatrics 
d. Paediatric surgery 
e. Gynaecology 
f. Reproductive specialist 
g. Others …………………………………… 
 
 
Q14. Which setting would best describe your practise? 
a. University/Academic Institution 
b. Government/Aided Institution 
c. Private practice affiliated with Institution 
d. Exclusive private practice 














Q16. How many new cancer diagnoses are made by you in a month, gender-wise?  
Please tick the appropriate box. 
No. / Gender <5 5-15 16-25 >25 
a. Male     
b. Female     
 
 
Q17. How many of the above new diagnoses are in the following age groups? 
Please tick the appropriate box. 
Age/Gender <15yrs 15-20yrs 21-25yrs 26-30yrs 31-35yrs >35yrs 
a. Male       
b. Female       
 
Q18. How many of the cancer patients come for follow-up? Please tick the appropriate box. 
No. /Gender <5 5-15 16-25 >25 
a. Male     
b. Female     
 
 
 
 
